deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 3-arm NCT02411448

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (RELAY)

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer

Sponsor: Eli Lilly and Company

Conditions Metastatic Non-Small Cell Lung Cancer
Interventions Erlotinib Gefitinib Osimertinib Placebo Ramucirumab
Updated 43 times since 2017 Last updated: Dec 24, 2025 Started: May 6, 2015 Primary completion: Jan 23, 2019 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Metastatic Non-Small Cell Lung Cancer and is currently ongoing. Eli Lilly and Company leads this study, which shows 43 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshot~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Nov 2019 · 8 months · monthly snapshot~Nov 2019 – ~Apr 2020 · 5 months · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Jun 2022 · 13 months · monthly snapshot~Jun 2022 – ~Jul 2023 · 13 months · monthly snapshot~Jul 2023 – ~Apr 2024 · 9 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Apr 2025 · 59 days · monthly snapshot~Apr 2025 – ~May 2025 · 30 days · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – ~Feb 2026 · 2 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

43 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE3

  2. Dec 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE3

  3. Sep 2025 — Dec 2025 [monthly]

    Active Not Recruiting PHASE3

  4. May 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

  5. Apr 2025 — May 2025 [monthly]

    Active Not Recruiting PHASE3

▶ Show 38 earlier versions

  1. Feb 2025 — Apr 2025 [monthly]

    Active Not Recruiting PHASE3

  2. Sep 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE3

  3. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  4. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  6. Jul 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE3

  7. Jun 2022 — Jul 2023 [monthly]

    Active Not Recruiting PHASE3

  8. May 2021 — Jun 2022 [monthly]

    Active Not Recruiting PHASE3

  9. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE3

  10. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  11. Nov 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE3

  12. Oct 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE3

  13. Sep 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE3

  14. Aug 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

  15. Jul 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE3

  16. Jun 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE3

  17. May 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE3

  18. Apr 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE3

  19. Nov 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE3

  20. Mar 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE3

  21. Jan 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE3

  22. Dec 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE3

  23. Nov 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  24. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  25. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  26. Jul 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  27. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  28. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  29. Apr 2018 — May 2018 [monthly]

    Recruiting PHASE3

  30. Mar 2018 — Apr 2018 [monthly]

    Recruiting PHASE3

  31. Dec 2017 — Mar 2018 [monthly]

    Recruiting PHASE3

  32. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  33. Aug 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  34. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  35. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

  36. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  37. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE3

  38. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

May 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adana, Turkey (Türkiye) , Akashi, Japan , Amagashiki, Japan , Asahikawa, Japan , Athens, Greece , Aviano, Italy , Barcelona, Spain , Bari, Italy , Berlin, Germany , Bologna, Italy and 79 more locations